COVID-19 trials registries data warehouse

http://en.irct.ir/trial/47300

Dr. Mohammadreza Naghipour

research@gums.ac.ir

2020-05-02

Completed

RCT

Randomized

Parallel

Blind label

single-center

Treatment

َAll of the patients admitted to Razi hospital of Rasht and diagnosed for COVID-19 in April-March 2020 18 years old and more ّFever (oral temperature more than 37.8) At least one of the following criteria Respiratory rate 24 and more per minute At rest SPO2 fewer than 94 PCR positive Pulmonary involvement in CT or chest X-ray

Those who aren't willing to participate in the study based on personal satisfaction concomitant use of an anti-psychotic drug History of epileptic disorders Parkinson's Disease Dementia Symptomatic hepatic dysfunction Allergic reaction to Phenothiazines History of pheochromocytoma Any major drug-interaction between routine-taken drugs with trifluoperazine Pregnancy and breastfeeding Previous COVID-19 treatment Multi-organ failure evidences Need to mechanical ventilation on entrance to the study eGFR< 50 mL/min

2

Rasht University of Medical Sciences

18

100

Iran

Severe disease at enrollment

6: Severe disease at enrollment

70

Time to clinical improvment: normalization of body temperature to 37.2 and lower Time to clinical improvment: normalization of respiratory rate to 24 and fewer Time to clinical improvment: Oxygen saturation of 94% and more

Phase 2/Phase 3

[{"arm_notes": "", "treatment_id": 1316, "treatment_name": "Trifluoperazine", "treatment_type": "Central nervous system agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]